University Cardiology Department, Medical School, Democritus University of Thrace, Voulgaroktonou 23, 68100 Alexandroupolis, Greece.
Qual Life Res. 2012 Feb;21(1):143-53. doi: 10.1007/s11136-011-9932-5. Epub 2011 May 20.
Assessment of circulating levels of collagen-derived peptides has been proposed as a useful tool to monitor indirectly myocardial collagen metabolism in chronic heart failure (CHF) patients. The potential link between circulating concentrations of collagen metabolism biomarkers and health-related quality of life (HRQOL) has not been adequately evaluated. With the present study, we investigated the association between serum levels of collagen-derived peptides and HRQOL.
We studied 280 consecutive outpatients (of mean age 67 ± 10 years, 180 men) with CHF. Serum concentrations of carboxy-terminal telopeptide of collagen type I (CITP)-a marker of collagen type I degradation-were measured in all patients both at baseline and during a period of 6 months follow-up. HRQOL was assessed by Minnesota living with heart failure questionnaire (MLHFQ).
CITP levels were significantly associated with MLHFQ scores both at baseline (r = 0.231, P < 0.001) and at 6 months follow-up (r = 0.145, P = 0.044). CITP levels remained significantly associated with MLHFQ score in multivariable linear regression analysis. Higher CITP levels were observed with higher MLHFQ scores (poor HRQOL) both at baseline (P = 0.001) and at 6 months (P = 0.041). Unadjusted analysis demonstrated a significant relationship between increasing CITP levels during 6 months follow-up and worsening HRQOL (r = 0.204, P = 0.001). The aforementioned correlation remained significant in multivariable linear regression analysis.
Our findings show that increased CITP levels are associated with poorer HRQOL in patients with CHF. These findings are consistent with a link between a pathophysiologic mechanism, i.e., collagen metabolism and patient self-assessed health status in CHF.
评估循环胶原肽水平已被提议作为一种间接监测慢性心力衰竭（CHF）患者心肌胶原代谢的有用工具。循环胶原代谢生物标志物浓度与健康相关生活质量（HRQOL）之间的潜在联系尚未得到充分评估。本研究旨在探讨血清胶原肽水平与 HRQOL 之间的关系。
我们研究了 280 例连续的门诊 CHF 患者（平均年龄 67±10 岁，180 名男性）。所有患者均在基线和 6 个月随访期间测量了Ⅰ型胶原羧基末端肽（CITP）-Ⅰ型胶原降解标志物的血清浓度。通过明尼苏达州心力衰竭生活质量问卷（MLHFQ）评估 HRQOL。
CITP 水平与基线时的 MLHFQ 评分显著相关（r=0.231，P<0.001），与 6 个月随访时的 MLHFQ 评分显著相关（r=0.145，P=0.044）。多变量线性回归分析显示，CITP 水平与 MLHFQ 评分仍显著相关。在基线时（P=0.001）和 6 个月时（P=0.041），较高的 CITP 水平与较高的 MLHFQ 评分（较差的 HRQOL）相关。未调整分析显示，6 个月随访期间 CITP 水平升高与 HRQOL 恶化呈显著正相关（r=0.204，P=0.001）。多变量线性回归分析中上述相关性仍然显著。
我们的研究结果表明，CHF 患者 CITP 水平升高与 HRQOL 较差相关。这些发现与胶原代谢的病理生理机制与 CHF 患者自我评估的健康状况之间存在联系一致。
